9

             SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549


                          FORM 10-Q


     QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE
               SECURITIES EXCHANGE ACT OF 1934

      For Quarter Ended                  March 31, 2005

      Commission file number             33-56574


                       DIASENSE, INC.
   (Exact name of registrant as specified in its charter)



   Pennsylvania                                25-1605848
  (State or other jurisdiction               (IRS Employer
of incorporation or organization)        Identification no.)


  2275 Swallow Hill Road, Bldg. 2500; Pittsburgh, PA 15220
 (Address of principal executive offices)       ( Zip Code)

                       (412) 279-1059
     Registrant's telephone number, including area code

     Indicate by check mark whether the registrant  (1)  has
filed  all  reports required to be filed by  section  13  or
15(d)  of  the  Securities Exchange Act of 1934  during  the
preceding  12  months (or for such shorter period  that  the
registrant was required to file such reports), and  (2)  has
been  subject to such filing requirements for  the  past  90
days.

                    Yes            No   X

     As  of  March 31, 2005, 22,980,051 shares of  Diasense,
Inc. common stock, par value $.01 were outstanding.


<PAGE>2


 					   DIASENSE,INC.
                         (A Development Stage Company)

                          Consolidated Balance Sheets


<TABLE>
<CAPTION>

                                                  (Unaudited)
                                                    March 31,   September 30,
               ASSETS                                 2005           2004
                                                   -----------    -----------
Current assets
  Cash                                             $     3,747    $         -

Other Assets
  Investment                                                 -              -
                                                   -----------     ----------
               TOTAL ASSETS                        $     3,747    $         -
                                                   ===========     ==========

               LIABILITIES and STOCKHOLDERS' EQUITY (DEFICIENCY)

Current liabilities
  Accounts payable                                 $     5,000     $    5,000
  Accrued interest on demand notes                      75,096              -
  Demand notes payable to majority shareholder       1,987,936      1,954,936
                                                     -----------    -----------
               Total current liabilities             2,068,032      1,959,936

Commitment and Contingencies

Stockholders' equity (deficiency)
  Preferred stock, 1,000,000 shares authorized,
   none issued.                                              -              -
  Common stock, 40,000,000 shares
   of $.01 par value authorized; issued and
   outstanding 22,980,051 at March 31, 2005 and
   Sep. 30, 2004                                       229,801        229,801
  Additional paid-in capital                        43,061,189     41,509,499
  Warrants                                           2,275,788      3,827,478
  Deficit accumulated during the  development stage(47,631,063)   (47,526,714)
                                                    -----------    -----------
                                                    (2,064,285)    (1,959,936)
                                                    -----------    -----------
TOTAL LIABILITIES AND
  STOCKHOLDERS'EQUITY (DEFICIENCY)                 $     3,747    $         -
                                                    ===========    ===========
<FN>

The accompanying notes are an integral part of this statement.

<PAGE>3
                                 Diasense, Inc.
                         (A Development Stage Company)

                      CONSOLIDATED STATEMENTS OF OPERATIONS


<CAPTION>

                                         For the six months ended    For the three months ended         From July 5, 1989
                                              March 31,                    March 31,                    (inception) thru
                                          2005        2004            2005             2004              March 31, 2005
                                       ---------    ---------      ----------       -----------         ----------------
<S>                                   <C>         <C>            <C>                <C>                <C>

Research and development expenses     $    -       $     -        $      -          $      -             $ 10,556,405

General and administrative expenses      29,253          -             22,835              -               16,906,012

Warrant extensions                         -             -               -                 -               17,890,676

Technology and patent rights acquired      -             -               -                 -                2,650,000

Interest expense                         75,096          -             34,749              -                   86,821

Loss on unconsolidated subsidiaries        -             -               -                 -                  575,412

Impairment Loss                            -             -               -                 -                  690,124

Amortization of Goodwill                   -             -               -                 -                  535,057

Other income                               -             -               -                 -               (1,042,997)

Other expense                              -             -               -                 -                   37,405

Gain from sale of MicroIslet Stock         -             -               -                 -               (1,283,852)
                                       ----------   ---------     -----------       --------------      ---------------
Net Loss                              $(104,349)   $     -        $   (57,584)      $      -             $(47,601,063)
                                       ==========   =========     ===========       =============       ===============
Net Loss per common share             $   (0.00)   $     -        $     (0.00)      $      -             $      (2.27)
                                       ==========   =========     ===========       =============       ===============

<FN>
The accompanying notes are an integral part of this statement.

</TABLE>
<PAGE>4
<TABLE>

                                 Diasense, Inc.
                         (A Development Stage Company)

                      CONSOLIDATED STATEMENT OF CASH FLOWS

<CAPTION>

                                         For the six months ended     For the three months ended   From July 5, 1989
                                        March 31,         March 31,  March 31,          March 31,  (inception) thru
                                          2005              2004        2005               2004    March 31, 2005
                                         -------------------------   ----------------------------  ------------------
<S>                                     <C>          <C>            <C>             <C>            <C>

Cash flows from operating activities:
 Net loss                                $(104,349)    $        -     $(57,584)      $        -     $  (47,601,063)
 Adjustments to reconcile net loss to net
 cash used by operating activities:
  Depreciation                                   -              -            -                -             90,047
  Amortization                                   -              -            -                -            535,057
  Impairment loss                                -              -            -                -            704,491
  Gain on sale of MicroIslet stock               -              -            -                -         (1,283,852)
  Loss on unconsolidated subsidiaries            -              -            -                -            575,412
  Stock issued in exchange for services          -              -            -                -            138,950
  Stk issued for License & Marketing Agreement   -              -            -                -             80,000
  Warrants issued for services                   -              -            -                -            513,915
  Warrant extensions                             -              -            -                -         17,890,676
  Inventory deposit - BICO                       -              -            -                -         (1,000,000)
  Increase in accrued interest              75,096              -       34,749                -             75,096
  Increase in accounts payable                   -              -            -                -              5,000
                                          ----------     ---------     ---------      -----------  ----------------
Net cash used in operating activities      (29,253)             -      (22,835)               -        (29,276,271)

Cash flows from investing activities:
  Disposal of property and equipment             -              -            -                -            175,000
  Purchase of property and equipment             -              -            -                -           (279,413)
  Investment - MicroIslet                        -              -            -                -         (1,600,000)
  Investment - Diabecore                         -              -            -                -           (987,468)
  Proceeds from sale of MicroIslet stock         -              -            -                -          2,070,726
  Increasein notes rec-related parties           -              -            -                -           (125,000)
  Increasein interest rec-related parties        -              -            -                -            (13,538)
                                          ----------     ---------     ---------      -----------  ----------------
Net cash used in investing activities            -              -            -                -           (759,693)

Cash flows from financing activities:
  Proceeds from notes payable               33,000              -       26,000                -             33,000
  Advances to BICO                               -              -            -                -         (7,498,369)
  Repayment of advances to BICO                  -              -            -                -          9,203,493
  Advances from BICO, net                        -              -            -                -         14,496,167
  Repayment of advances from BICO                -              -            -                -         (2,041,231)
  Proceeds from issuance of common stock         -              -            -                -         10,971,834
  Proceeds from issuance of common stk to BICO   -              -            -                -          4,200,000
  Proceeds from warrants exercised               -              -            -                -            118,066
  Purchase from treasury stock                   -              -            -                -            (35,000)
  Proceeds from Regulation S                     -              -            -                -            288,751
  Proceeds from issuance of notes payable        -              -            -                -            303,000
                                          ----------     ---------     ---------      -----------  ----------------
Net cash provided by financing activities   33,000              -       26,000                -         30,039,711
                                          ----------     ---------     ---------      -----------  ----------------
Net increase in cash and cash equiv.         3,747              -        3,165                -              3,747
Cash and cash equivalents at beg of period       -              -          582                -                  -
                                          ----------     ---------     ---------      -----------  ----------------
Cash and cash equivalents at end
    of period                             $  3,747       $      -      $ 3,747        $       -     $        3,747
                                          ==========     =========     =========      ===========   ===============

The accompanying notes are an integral part of this statement.

</TABLE>





                    DIASENSE, INC.

         NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


NOTE A - Basis of Presentation

The accompanying financial statements of Diasense, Inc. (the
"Company")  have been prepared in accordance with  generally
accepted   accounting  principles  for   interim   financial
information, and with the instructions to Form 10-Q and Rule
10-01  of Regulation S-X.  Accordingly, they do not  include
all  of  the information and footnotes required by generally
accepted   accounting  principles  for  complete   financial
statements.   In the opinion of management, all  adjustments
(consisting   of   normal  recurring  accruals)   considered
necessary  for a fair presentation have been included.   For
further  information, refer to the financial statements  and
footnotes included in the Company's annual report on Form 10-
K for the fiscal year ended September 30, 2004.

NOTE B - Organization

The  Company was incorporated on July 5, 1989 as  a  wholly-
owned   subsidiary  of  BICO,  Inc.  (parent).   BICO  owned
approximately 52% of the stock of the Company until July 23,
2004  when  BICO  sold  its  entire  ownership  interest  to
Dominion  Assets, LLC.  The Company's activities  have  been
focused on developing a noninvasive glucose sensor (Sensor).
The  sensor would use infrared technology to measure glucose
levels  in blood without requiring the user to take a  blood
sample. However, all of these activities were curtailed when
BICO  ceased operations and filed for Chapter 11  bankruptcy
in March 2003.

NOTE C - Income (Net Loss) Per Common Share

Net loss per common share is based on the weighted average
number of outstanding common shares, which amounted to
22,980,051 and 22,980,051 for the periods ended March 31,
2005 and March 31, 2004, respectively. The loss per share
does not include common stock equivalents since the effect
would be anti-dilutive.

From July 5, 1989 (inception) to March 31, 2005, net loss
per common share is based on the weighted average number of
common shares outstanding and the number of common shares
issuable on the exercise of 1,708,000 warrants issued in
1992; reduced by 488,000 common shares that were assumed to
have been purchased with the proceeds from the exercise of
the warrants at an assumed price of $3.50 per share.  The
inclusion of the warrants in the loss per share calculation
is required by the rules of the Securities and Exchange
Commission relative to the initial registration statement,
which included the Company's financial statements through
the period ended March 31, 1993.  The registration statement
became effective July 19, 1993.  The weighted average number
of common shares including the effect of the conversion of
the warrants amounted to 20,961,798 for the period from July
5, 1989 (inception) to March 31, 2005

NOTE D - Operations

In April 2005, Diasense resumed development of the Sensor
but has not, as yet, achieved a commercially marketable
product. The ability of Diasense to continue in existence is
dependent on its having sufficient financial resources to
restore and maintain operations, to complete the research
and development necessary to successfully bring the Sensor
to market, and for marketplace acceptance. Diasense has no
other commercial products and is dependent on the successful
development of the Sensor technology. Diasense has had no
sales of its common stock over the last five fiscal years.
Until BICO's bankruptcy in March 2003, Diasense's operations
were funded by advances from BICO.

Diasense is in the development stage, and accordingly, it
has presented cumulative information on results of
operations, cash flows, and changes in stockholders' equity
since inception.

Diasense has incurred significant losses and negative cash
flows from operations from inception through March 31, 2005
and has a significant accumulated deficit as of March 31,
2005, raising substantial doubt about its ability to
continue as a going concern. Since 1997, Diasense had been
financially dependent upon BICO and therefore BICO's ability
to raise money through its stock sales to support its
operations. With the curtailment of funding from BICO due to
BICO's bankruptcy in March 2003, Diasense will be required
to find other funding in order to continue as a going
concern. The Company plans to liquidate assets to the extent
necessary to continue operations.

NOTE E - Note Payble to Majority Shareholder

In connection with the purchase of the 52% ownership of
Diasense by Dominion Assets, LLC. from BICO, an intercompany
payable of $1,954,936 from Diasense to BICO was assigned to
Dominion Assets, LLC. (Dominion). This liability was
documented by a note payable on demand without interest.
After demand for payment was made by Dominion Assets, LLC,
the demand note was amended effective September 28, 2004.
Under the terms of the amended demand note Diasense now owes
a principle amount of $1,954,936 with interest calculated at
a rate of 8% per annum. The indebtedness is collateralized
by all of Diasense's assets. During the six months ended
March 31, 2005, Dominion loaned Diasense an additional
$33,000 to provide funding for general and administrative
expenses. This amount is also payable on demand with
interest accrued at a rate of 8%.





                       DIASENSE, INC.

Management's Discussion and Analysis of Financial Condition
and Cash Flows

Liquidity and Capital Resources

     Our entire funding for the six months ended March 31,
2005 of $33,000 came from advances on a demand loan from our
majority shareholder, Dominion Assets, LLC (Dominion). We do
not know if Dominion will continue to be willing or able to
continue financing our operations.

     Because we still don't have any revenue sources, we
will have to find additional financing that we'll use to
finance development of, and proceed to manufacture, our
noninvasive glucose sensor. In prior years, we were
dependent upon BICO to support all our sensor-related
activity, but BICO discontinued our funding in 2002, filed
bankruptcy in March 2003 and sold its interest in our
Company in May 2004. As a result, we had to stop all our activity.
However in April 2005 we resumed development of the Sensor but
we have not as yet achieved a commercially marketable product.
If we are not able to obtain additional financing from
Dominion or other outside sources,we will not be able to continue
operations.

Results of Operations

     We did not have any operations during the three and six
month period ended March 31, 2005.

     General and administrative expenses totaled $22,835 and
$29,253  during the three and six month period  ended  March
31,  2005.  The increase resulted primarily from efforts  to
bring our financial reporting current and to restore certain
patent rights.

     Interest  expense of $34,749 and $75,096 was recognized
in the three and six month periods ended March 31, 2005 as a
result  of  the  accrual  of interest  on  our  demand  note
obligations  to  our majority shareholder (Dominion  Assets,
LLC.)  We  had  no  interest  bearing  obligations  for  the
corresponding periods in our prior fiscal year.

Subsequent Event

      In  May  2005 we sold our entire interest in Diabecore
Medical  Inc.  (Diabecore) back to  Diabecore  for  a  total
purchase price of $73,500 (Canadian). We received 75% of the
sale price ($42,999 US) in May 2005.




                       DIASENSE, INC.


                PART II -- OTHER INFORMATION

Item 1.        Legal Proceedings
               None.

Item 2.        Changes in Securities
               None.

Item 3.        Defaults Upon Senior Securities
               None.

Item 4.        Submission of Matters to a Vote of Security
Holders
               None.

Item 5.        Other Information
               None.

Item 6.        Reports on Form 8-K
               None.



SIGNATURES


     Pursuant to the requirements of the Securities Exchange
Act  of 1934, the registrant has duly caused this report  to
be  signed  on its behalf by the undersigned thereunto  duly
authorized on this 13th day of May 2005.


                              DIASENSE, INC.

                              By /s/ Anthony Paterra
                                   Anthony Paterra
                                Chief Executive Officer and
                                Director (principal
                                executive officer, principal
                                financial officer and
                                principal accounting
                                    officer)